Science Corp’s PRIMA Chip Gains EU Clearance: A New Era for Vision Restoration

Science Corporation has secured European regulatory approval for its PRIMA chip, offering a direct solution to vision loss caused by age‑related macular degeneration.

European Green Light for Vision Restoration

The regulator’s nod follows the company’s 2024 clinical trials in France, accelerating the path to commercial rollout.

Financial Framework and Pricing Dynamics

■Target unit price set in the hundreds of thousands of dollars range.

■Aiming for a $100 million annual revenue to underpin a sustainable business model.

■Ongoing reimbursement negotiations with European health‑care providers.

Regulatory Landscape and Market Expansion

■The U.S. Food and Drug Administration granted an “expedited review” designation, paving the way for use in two rare forms of blindness by 2025.

■First procedures slated for September 2024 in Germany.

Competitive Landscape and Technology Roadmap

■Current glasses require a battery pack, making the system heavier than Meta’s AR glasses.

■Development of a next‑gen chip and lighter eyewear aims to close the gap with Meta’s AR vision.

■Collaboration with Yale Medical School’s neurosurgery department to develop directly implanted bio‑hybrid brain sensors.

Gökberk Uçar – Aviation Logistics and Freight Specialist: PRIMA’s high price point and intricate supply chain will initially limit access to advanced health‑care systems. Over the long term, the device’s success could set a new benchmark in the medical‑technology market, prompting a reshuffle of logistics networks that handle delicate medical equipment. This scenario creates fresh opportunities for air cargo carriers specializing in medical freight, while also fostering a regulatory‑driven market ecosystem.